Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis

Wyeth is now a wholly owned subsidiary of Pfizer384 enrolled

Overview

This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.

Study Type

OBSERVATIONAL

Enrollment

384

Conditions

Psoriatic Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Patients both genders over 18 years old * Patients with PsA diagnosis Exclusion criteria: * Patients with PsA that suffer from other rheumatologic diseases or non-concomitant rheumatologic diseases that the investigator considers not to be appropriate for the study. * Patients with any medical or physical condition (cognitive damage or difficulties for understanding) that create difficulties for reading and completing the questionnaires described in the protocol. * Patients that in the study period are taking part in another clinical trial.

Locations (1)

Unnamed facility

Reus, Tarragona, Spain

Outcomes

Primary Outcomes

Prevalence of anxiety and/or depression disorders in patients suffering from PsA in Spain as measured by the Hospital Anxiety and Depression Scale (HAD)

Time frame: 12 months

Secondary Outcomes

To assess the relation between the PsA severity and the presence of anxiety and/or depression disorders in patients suffering from PsA in Spain.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.